Jump to content

Xenon gas MRI: Difference between revisions

From Wikipedia, the free encyclopedia
Content deleted Content added
Citation bot (talk | contribs)
Alter: title. Add: doi-access. | Use this bot. Report bugs. | Suggested by Headbomb | #UCB_toolbar
update medical; remove stale FDA; remove text without citations
Line 1: Line 1:
{{Short description|Xenon Gas MRI}}
{{Short description|Xenon Gas MRI}}
{{Use dmy dates|date=December 2022}}
{{Use dmy dates|date=December 2022}}
{{cs1 config |name-list-style=vanc |display-authors=6}}
Hyperpolarized [[Isotopes of xenon|<sup>129</sup>Xe]] gas magnetic resonance imaging ([[Magnetic resonance imaging|MRI]]) is a medical imaging technique used to visualize the [[anatomy]] and [[physiology]] of body regions that are difficult to image with standard proton MRI. In particular, the lung, which lacks substantial density of protons, is particularly useful to be visualized with <sup>129</sup>Xe gas MRI. This technique has promise as an early-detection technology for chronic lung diseases and imaging technique for processes and structures reliant on dissolved gases.<ref name=":0">{{cite journal | vauthors = Roos JE, McAdams HP, Kaushik SS, Driehuys B | title = Hyperpolarized Gas MR Imaging: Technique and Applications | journal = Magnetic Resonance Imaging Clinics of North America | volume = 23 | issue = 2 | pages = 217–229 | date = May 2015 | pmid = 25952516 | pmc = 4428591 | doi = 10.1016/j.mric.2015.01.003 }}</ref><ref name=":1" /> <sup>129</sup>Xe is a stable, naturally occurring isotope of xenon with 26.44% isotope abundance. It is one of two Xe isotopes, along with <sup>131</sup>Xe, that has non-zero [[Spin (physics)|spin]], which allows for [[Nuclear magnetic resonance|magnetic resonance]]. <sup>129</sup>Xe is used for MRI because its large [[Atomic orbital|electron cloud]] permits [[Hyperpolarization (physics)|hyperpolarization]] and a wide range of chemical shifts. The hyperpolarization creates a large signal intensity, and the wide range of chemical shifts allows for identifying when the <sup>129</sup>Xe associates with molecules like hemoglobin. <sup>129</sup>Xe is preferred over <sup>131</sup>Xe for MRI because <sup>129</sup>Xe has spin 1/2 (compared to 3/2 for <sup>131</sup>Xe), a longer [[Magnetic resonance imaging|T1]], and 3.4 times larger [[gyromagnetic ratio]] (11.78&nbsp;MHz/T).<ref>{{cite journal | vauthors = Oros AM, Shah NJ | title = Hyperpolarized xenon in NMR and MRI | journal = Physics in Medicine and Biology | volume = 49 | issue = 20 | pages = R105–R153 | date = October 2004 | pmid = 15566166 | doi = 10.1088/0031-9155/49/20/r01 | s2cid = 250857751 | url = http://juser.fz-juelich.de/record/40261/files/53606.pdf }}</ref>
Hyperpolarized [[Isotopes of xenon|<sup>129</sup>Xe]] gas magnetic resonance imaging ([[Magnetic resonance imaging|MRI]]) is a medical imaging technique used to visualize the [[anatomy]] and [[physiology]] of body regions that are difficult to image with standard proton MRI. In particular, the lung, which lacks substantial density of protons, is particularly useful to be visualized with <sup>129</sup>Xe gas MRI. This technique has promise as an early-detection technology for chronic lung diseases and imaging technique for processes and structures reliant on dissolved gases.<ref name=":0">{{cite journal | vauthors = Roos JE, McAdams HP, Kaushik SS, Driehuys B | title = Hyperpolarized Gas MR Imaging: Technique and Applications | journal = Magnetic Resonance Imaging Clinics of North America | volume = 23 | issue = 2 | pages = 217–229 | date = May 2015 | pmid = 25952516 | pmc = 4428591 | doi = 10.1016/j.mric.2015.01.003 }}</ref><ref name=":1" /> <sup>129</sup>Xe is a stable, naturally occurring isotope of xenon with 26.44% isotope abundance. It is one of two Xe isotopes, along with <sup>131</sup>Xe, that has non-zero [[Spin (physics)|spin]], which allows for [[Nuclear magnetic resonance|magnetic resonance]]. <sup>129</sup>Xe is used for MRI because its large [[Atomic orbital|electron cloud]] permits [[Hyperpolarization (physics)|hyperpolarization]] and a wide range of chemical shifts. The hyperpolarization creates a large signal intensity, and the wide range of chemical shifts allows for identifying when the <sup>129</sup>Xe associates with molecules like hemoglobin. <sup>129</sup>Xe is preferred over <sup>131</sup>Xe for MRI because <sup>129</sup>Xe has spin 1/2 (compared to 3/2 for <sup>131</sup>Xe), a longer [[Magnetic resonance imaging|T1]], and 3.4 times larger [[gyromagnetic ratio]] (11.78&nbsp;MHz/T).<ref>{{cite journal | vauthors = Oros AM, Shah NJ | title = Hyperpolarized xenon in NMR and MRI | journal = Physics in Medicine and Biology | volume = 49 | issue = 20 | pages = R105–R153 | date = October 2004 | pmid = 15566166 | doi = 10.1088/0031-9155/49/20/r01 | s2cid = 250857751 | url = http://juser.fz-juelich.de/record/40261/files/53606.pdf }}</ref>


Line 8: Line 9:
{{Infobox drug
{{Infobox drug
| drug_name = Xenon Xe 129 hyperpolarized
| drug_name = Xenon Xe 129 hyperpolarized
| INN =
| type = <!-- empty -->
| image =
| image =
| width =
| width =
Line 20: Line 19:
| Drugs.com =
| Drugs.com =
| MedlinePlus =
| MedlinePlus =
| licence_CA = <!-- Health Canada may use generic or brand name (generic name preferred) -->
| licence_EU = <!-- EMA uses INN (or special INN_EMA) -->
| DailyMedID = Xenon Xe 129
| DailyMedID = Xenon Xe 129
| licence_US = <!-- FDA may use generic or brand name (generic name preferred) -->
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_AU_comment =
| pregnancy_AU_comment =
| pregnancy_category =
| pregnancy_category =
| routes_of_administration =
| routes_of_administration = [[Inhalation administration|Inhalation]]
| class =
| class =
| ATCvet =
| ATCvet =
Line 104: Line 100:
}}
}}


Xenon Xe 129 hyperpolarized, sold under the brand name '''Xenoview''', is a [[Hyperpolarization (physics)|hyperpolarized]] [[contrast agent]] [[indicated]] for use with magnetic resonance imaging (MRI) for evaluation of [[lung ventilation]], and approved for people aged 12 years of age and older.<ref name="Xenoview FDA label" /> It was approved on December 23, 2022.<ref>{{cite news |last1=plc |first1=Polarean Imaging |title=FDA Approves Polarean's XENOVIEW™ (xenon Xe 129 hyperpolarized) for use with MRI for the Evaluation of Lung Ventilation |url=https://www.globenewswire.com/news-release/2022/12/28/2580194/0/en/FDA-Approves-Polarean-s-XENOVIEW-xenon-Xe-129-hyperpolarized-for-use-with-MRI-for-the-Evaluation-of-Lung-Ventilation.html |access-date=31 August 2023 |work=GlobeNewswire News Room |date=28 December 2022 |language=en}}</ref>
Xenon Xe 129 hyperpolarized, sold under the brand name '''Xenoview''', is a [[Hyperpolarization (physics)|hyperpolarized]] [[contrast agent]] [[indicated]] for use with magnetic resonance imaging (MRI) for evaluation of [[lung ventilation]], and approved for people aged twelve years of age and older.<ref name="Xenoview FDA label" /><ref name="Drug Trials Snapshots: Xenoview">{{cite web | title=Drug Trials Snapshots: Xenoview | website=U.S. Food and Drug Administration | date=23 December 2022 | url=https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-xenoview | access-date=8 January 2024}} {{PD-notice}}</ref> It was approved for medical use in the US in December 2022.<ref>{{cite press release |title=FDA Approves Polarean's Xenoview (xenon Xe 129 hyperpolarized) for use with MRI for the Evaluation of Lung Ventilation |url=https://www.globenewswire.com/news-release/2022/12/28/2580194/0/en/FDA-Approves-Polarean-s-XENOVIEW-xenon-Xe-129-hyperpolarized-for-use-with-MRI-for-the-Evaluation-of-Lung-Ventilation.html |access-date=31 August 2023 |publisher=Polarean Imaging |via=GlobeNewswire |date=28 December 2022 }}</ref>


The US [[Food and Drug Administration]] (FDA) considers it to be a [[first-in-class medication]].<ref name="New Drug Therapy Approvals 2022">{{cite web | title=Advancing Health Through Innovation: New Drug Therapy Approvals 2022 | website=U.S. [[Food and Drug Administration]] (FDA) | date=10 January 2023 | url=https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/new-drug-therapy-approvals-2022 | access-date=22 January 2023}} {{PD-notice}}</ref>
The US [[Food and Drug Administration]] (FDA) considers it to be a [[first-in-class medication]].<ref name="New Drug Therapy Approvals 2022">{{cite web | title=Advancing Health Through Innovation: New Drug Therapy Approvals 2022 | website=U.S. [[Food and Drug Administration]] (FDA) | date=10 January 2023 | url=https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/new-drug-therapy-approvals-2022 | access-date=22 January 2023}} {{PD-notice}}</ref>

The FDA approved Xenoview based on evidence from two clinical trials in 83 participants with various lung disorders who were being evaluated for possible lung resection or lung transplantation.<ref name="Drug Trials Snapshots: Xenoview" /> The trials were conducted at five sites in the United States and assessed both efficacy and safety of Xenoview.<ref name="Drug Trials Snapshots: Xenoview" /> Xenoview was evaluated in two clinical trials of 83 adults with pulmonary disorders who each underwent sequential lung ventilation imaging with Xenoview with MRI and an approved comparator, Xe 133 scintigraphy.<ref name="Drug Trials Snapshots: Xenoview" /> In study 1, participants were imaged to help plan possible lung resection.<ref name="Drug Trials Snapshots: Xenoview" /> To determine the benefit of Xenoview, estimates of the percentage of lung ventilation predicted to remain after surgery made with Xenoview with MRI and comparator imaging were evaluated for equivalence.<ref name="Drug Trials Snapshots: Xenoview" /> In study 2, participants were imaged to help plan possible lung transplantation.<ref name="Drug Trials Snapshots: Xenoview" /> To determine the benefit of Xenoview, estimates of the percentage of lung ventilation contributed by the right lung made with Xenoview with MRI and comparator imaging were evaluated for equivalence.<ref name="Drug Trials Snapshots: Xenoview" />


== History ==
== History ==
Hyperpolarized <sup>129</sup>Xe is achieved through [[Hyperpolarization (physics)|spin-exchange optical pumping]], a technique developed by Grover et al. in 1978<ref>{{Cite journal| vauthors = Grover BC |date=1978-02-06|title=Noble-Gas NMR Detection through Noble-Gas-Rubidium Hyperfine Contact Interaction |journal=Physical Review Letters|language=en|volume=40|issue=6|pages=391–392|doi=10.1103/PhysRevLett.40.391|bibcode=1978PhRvL..40..391G|issn=0031-9007}}</ref> and improved by Happer et al. in 1984.<ref>{{Cite journal| vauthors = Happer W, Miron E, Schaefer S, Schreiber D, Van Wijngaarden WA, Zeng X |date=1984-06-01|title=Polarization of the nuclear spins of noble-gas atoms by spin exchange with optically pumped alkali-metal atoms|url=https://link.aps.org/doi/10.1103/PhysRevA.29.3092|journal=Physical Review A|language=en|volume=29|issue=6|pages=3092–3110|doi=10.1103/PhysRevA.29.3092|bibcode=1984PhRvA..29.3092H|issn=0556-2791}}</ref> Quantification of <sup>129</sup>Xe polarization was first described in 1982 by Bhaskar et al.<ref>{{Cite journal| vauthors = Bhaskar ND, Happer W, McClelland T |date=1982-07-05|title=Efficiency of Spin Exchange between Rubidium Spins and Xe 129 Nuclei in a Gas |journal=Physical Review Letters|language=en|volume=49|issue=1|pages=25–28|doi=10.1103/PhysRevLett.49.25|issn=0031-9007}}</ref> The use of hyperpolarized <sup>129</sup>Xe gas in MRI ex-vivo was first described by Albert et al. in 1994 using excised rat lungs.<ref>{{cite journal | vauthors = Marshall H, Stewart NJ, Chan HF, Rao M, Norquay G, Wild JM | title = In vivo methods and applications of xenon-129 magnetic resonance | journal = Progress in Nuclear Magnetic Resonance Spectroscopy | volume = 122 | pages = 42–62 | date = February 2021 | pmid = 33632417 | pmc = 7933823 | doi = 10.1016/j.pnmrs.2020.11.002 }}</ref> The first in-vivo human studies with <sup>129</sup>Xe MRI were published by Mugler et al. in 1997.<ref>{{cite journal | vauthors = Mugler JP, Driehuys B, Brookeman JR, Cates GD, Berr SS, Bryant RG, Daniel TM, de Lange EE, Downs JH, Erickson CJ, Happer W, Hinton DP, Kassel NF, Maier T, Phillips CD, Saam BT, Sauer KL, Wagshul ME | display-authors = 6 | title = MR imaging and spectroscopy using hyperpolarized 129Xe gas: preliminary human results | journal = Magnetic Resonance in Medicine | volume = 37 | issue = 6 | pages = 809–815 | date = June 1997 | pmid = 9178229 | doi = 10.1002/mrm.1910370602 | s2cid = 27232819 }}</ref>
Hyperpolarized <sup>129</sup>Xe is achieved through [[Hyperpolarization (physics)|spin-exchange optical pumping]], a technique developed by Grover et al. in 1978<ref>{{Cite journal| vauthors = Grover BC |date=1978-02-06|title=Noble-Gas NMR Detection through Noble-Gas-Rubidium Hyperfine Contact Interaction |journal=Physical Review Letters|volume=40|issue=6|pages=391–392|doi=10.1103/PhysRevLett.40.391|bibcode=1978PhRvL..40..391G|issn=0031-9007}}</ref> and improved by Happer et al. in 1984.<ref>{{Cite journal| vauthors = Happer W, Miron E, Schaefer S, Schreiber D, Van Wijngaarden WA, Zeng X |date=1984-06-01|title=Polarization of the nuclear spins of noble-gas atoms by spin exchange with optically pumped alkali-metal atoms|url=https://link.aps.org/doi/10.1103/PhysRevA.29.3092|journal=Physical Review A|volume=29|issue=6|pages=3092–3110|doi=10.1103/PhysRevA.29.3092|bibcode=1984PhRvA..29.3092H|issn=0556-2791}}</ref> Quantification of <sup>129</sup>Xe polarization was first described in 1982 by Bhaskar et al.<ref>{{Cite journal| vauthors = Bhaskar ND, Happer W, McClelland T |date=1982-07-05|title=Efficiency of Spin Exchange between Rubidium Spins and Xe 129 Nuclei in a Gas |journal=Physical Review Letters|volume=49|issue=1|pages=25–28|doi=10.1103/PhysRevLett.49.25|issn=0031-9007}}</ref> The use of hyperpolarized <sup>129</sup>Xe gas in MRI ex-vivo was first described by Albert et al. in 1994 using excised rat lungs.<ref>{{cite journal | vauthors = Marshall H, Stewart NJ, Chan HF, Rao M, Norquay G, Wild JM | title = In vivo methods and applications of xenon-129 magnetic resonance | journal = Progress in Nuclear Magnetic Resonance Spectroscopy | volume = 122 | pages = 42–62 | date = February 2021 | pmid = 33632417 | pmc = 7933823 | doi = 10.1016/j.pnmrs.2020.11.002 }}</ref> The first in-vivo human studies with <sup>129</sup>Xe MRI were published by Mugler et al. in 1997.<ref>{{cite journal | vauthors = Mugler JP, Driehuys B, Brookeman JR, Cates GD, Berr SS, Bryant RG, Daniel TM, de Lange EE, Downs JH, Erickson CJ, Happer W, Hinton DP, Kassel NF, Maier T, Phillips CD, Saam BT, Sauer KL, Wagshul ME | display-authors = 6 | title = MR imaging and spectroscopy using hyperpolarized 129Xe gas: preliminary human results | journal = Magnetic Resonance in Medicine | volume = 37 | issue = 6 | pages = 809–815 | date = June 1997 | pmid = 9178229 | doi = 10.1002/mrm.1910370602 | s2cid = 27232819 }}</ref>


<sup>129</sup>Xe MRI has largely begun to replace <sup>3</sup>He gas MRI, a very similar technology that uses hyperpolarized [[Helium-3|<sup>3</sup>He]] molecules instead of <sup>129</sup>Xe. Grossman et al. began human clinical trials for <sup>3</sup>He MRI in 1996. <sup>3</sup>He was originally touted as the better gas for hyperpolarized gas MRI because it is more polarizable and has no effects on the body.<ref name=":0"/> However, <sup>3</sup>He is mostly produced by the [[beta decay]] of [[tritium]] (<sup>3</sup>H), which is a product of nuclear warhead production. Additionally, <sup>3</sup>He is widely used by the U.S. military to detect smuggled plutonium.<ref>{{cite journal | vauthors = Albert MS, Balamore D | title = Development of hyperpolarized noble gas MRI | journal = Nuclear Instruments and Methods in Physics Research Section A | volume = 402 | issue = 2–3 | pages = 441–453 | date = 1998 | pmid = 11543065 | doi = 10.1016/s0168-9002(97)00888-7 | bibcode = 1998NIMPA.402..441A }}</ref> These combination of increasing scarcity and increasing demand have combined to make <sup>3</sup>He highly expensive, up to more than $1000 per liter.<ref>{{Cite web | vauthors = Adee S | date= 31 August 2010 |title=Physics Projects Deflate for Lack of Helium-3|url=https://spectrum.ieee.org/physics-projects-deflate-for-lack-of-helium3|access-date=2021-12-05|website=IEEE Spectrum|language=en}}</ref>
<sup>129</sup>Xe MRI has largely begun to replace <sup>3</sup>He gas MRI, a very similar technology that uses hyperpolarized [[Helium-3|<sup>3</sup>He]] molecules instead of <sup>129</sup>Xe. Grossman et al. began human clinical trials for <sup>3</sup>He MRI in 1996. <sup>3</sup>He was originally touted as the better gas for hyperpolarized gas MRI because it is more polarizable and has no effects on the body.<ref name=":0"/> However, <sup>3</sup>He is mostly produced by the [[beta decay]] of [[tritium]] (<sup>3</sup>H), which is a product of nuclear warhead production. Additionally, <sup>3</sup>He is widely used by the U.S. military to detect smuggled plutonium.<ref>{{cite journal | vauthors = Albert MS, Balamore D | title = Development of hyperpolarized noble gas MRI | journal = Nuclear Instruments and Methods in Physics Research Section A | volume = 402 | issue = 2–3 | pages = 441–453 | date = 1998 | pmid = 11543065 | doi = 10.1016/s0168-9002(97)00888-7 | bibcode = 1998NIMPA.402..441A }}</ref> These combination of increasing scarcity and increasing demand have combined to make <sup>3</sup>He highly expensive, up to more than $1000 per liter.<ref>{{Cite web | vauthors = Adee S | date= 31 August 2010 |title=Physics Projects Deflate for Lack of Helium-3|url=https://spectrum.ieee.org/physics-projects-deflate-for-lack-of-helium3|access-date=2021-12-05|website=IEEE Spectrum}}</ref>


== Safety ==
== Safety ==
Line 123: Line 121:
== Required modifications to conventional MRI ==
== Required modifications to conventional MRI ==
Traditional MR scanners need to be modified to detect <sup>129</sup>Xe, as <sup>129</sup>Xe has a lower gyromagnetic ratio of 11.77&nbsp;MHz/T compared to that of protons, 42.5&nbsp;MHz/T. Thus, the Larmor frequency of <sup>129</sup>Xe is much lower, which is difficult to detect with conventional narrow-band RF amplifiers set to proton's [[Larmor precession|Larmor frequency]]. Therefore, a broad-band [[RF power amplifier|RF amplifier]], for both excitation and receiving, is required.<ref name=":0" /> Additionally, the pulse sequence must also accommodate the difference in thermally-polarized protons and polarized <sup>129</sup>Xe.<ref name=":0" /><ref name=":3">{{cite journal | vauthors = Mugler JP, Altes TA | title = Hyperpolarized 129Xe MRI of the human lung | journal = Journal of Magnetic Resonance Imaging | volume = 37 | issue = 2 | pages = 313–331 | date = February 2013 | pmid = 23355432 | pmc = 3558952 | doi = 10.1002/jmri.23844 }}</ref> In proton MRI, a typical pulse sequence would involve a 90° flip then a subsequent [[Magnetic resonance imaging|T1 longitudinal relaxation]] to the external magnetic field. T1 relaxation in hyperpolarized gas involves the decay of magnetization and not the return to an external magnetic field, as in thermally-polarized protons.<ref name=":3" /> Therefore, after a 90° flip, a hyperpolarized gas nuclei's longitudinal relaxation is negligible, making the longitudinal magnetization remain zero after the flip. As a result, traditional 90° and 180° RF pulses are not desirable.<ref name=":0" /><ref name=":3" /> A low-angle RF pulse is therefore used to only remove a portion of the total available magnetization of the hyperpolarized <sup>129</sup>Xe gas. This produces comparable longitudinal magnetization between protons and <sup>129</sup>Xe gas.<ref name=":3" /> Furthermore, as an image needs to be acquired within a breath-hold, a fast pulse-sequences, or fast-gradient echos, are used to adequately sample the k-space.<ref name=":0" /><ref name=":3" />
Traditional MR scanners need to be modified to detect <sup>129</sup>Xe, as <sup>129</sup>Xe has a lower gyromagnetic ratio of 11.77&nbsp;MHz/T compared to that of protons, 42.5&nbsp;MHz/T. Thus, the Larmor frequency of <sup>129</sup>Xe is much lower, which is difficult to detect with conventional narrow-band RF amplifiers set to proton's [[Larmor precession|Larmor frequency]]. Therefore, a broad-band [[RF power amplifier|RF amplifier]], for both excitation and receiving, is required.<ref name=":0" /> Additionally, the pulse sequence must also accommodate the difference in thermally-polarized protons and polarized <sup>129</sup>Xe.<ref name=":0" /><ref name=":3">{{cite journal | vauthors = Mugler JP, Altes TA | title = Hyperpolarized 129Xe MRI of the human lung | journal = Journal of Magnetic Resonance Imaging | volume = 37 | issue = 2 | pages = 313–331 | date = February 2013 | pmid = 23355432 | pmc = 3558952 | doi = 10.1002/jmri.23844 }}</ref> In proton MRI, a typical pulse sequence would involve a 90° flip then a subsequent [[Magnetic resonance imaging|T1 longitudinal relaxation]] to the external magnetic field. T1 relaxation in hyperpolarized gas involves the decay of magnetization and not the return to an external magnetic field, as in thermally-polarized protons.<ref name=":3" /> Therefore, after a 90° flip, a hyperpolarized gas nuclei's longitudinal relaxation is negligible, making the longitudinal magnetization remain zero after the flip. As a result, traditional 90° and 180° RF pulses are not desirable.<ref name=":0" /><ref name=":3" /> A low-angle RF pulse is therefore used to only remove a portion of the total available magnetization of the hyperpolarized <sup>129</sup>Xe gas. This produces comparable longitudinal magnetization between protons and <sup>129</sup>Xe gas.<ref name=":3" /> Furthermore, as an image needs to be acquired within a breath-hold, a fast pulse-sequences, or fast-gradient echos, are used to adequately sample the k-space.<ref name=":0" /><ref name=":3" />

Notably, there is a large amount of motion when the lungs expand and contract. This motion prevents getting a high-quality image. To alleviate this problem, the full scan must be accomplished within a 10-15 second breath hold, so <sup>129</sup>Xe gas MRI scans are sometimes of lower resolution than the clinical standard. Additionally, another constraint is that flipping the protons with the B1 gradient occurs at about a quarter of the speed of proton MRI. This occurs due to the difference between the Larmor frequencies. Ultimately, the time constraints of these images requires different and novel [[MRI sequence]] designs.


== Applications ==
== Applications ==
Line 140: Line 136:


[[File:Xe_Gas_MRI_of_Healthy_and_Diseased_Lungs.png|thumb|Xe Gas MRI of Healthy and Diseased Lungs. Colors show different intensities of Xe Gas.]]
[[File:Xe_Gas_MRI_of_Healthy_and_Diseased_Lungs.png|thumb|Xe Gas MRI of Healthy and Diseased Lungs. Colors show different intensities of Xe Gas.]]
<sup>129</sup>Xe gas MRI is being researched as a diagnostic test for respiratory diseases, such as [[Chronic obstructive pulmonary disease|COPD]], [[asthma]], and [[emphysema]]. Currently, [[spirometry]] pulmonary function tests are used to determine the condition of lung function.<ref>{{cite journal | vauthors = Ranu H, Wilde M, Madden B | title = Pulmonary function tests | journal = The Ulster Medical Journal | volume = 80 | issue = 2 | pages = 84–90 | date = May 2011 | pmid = 22347750 | pmc = 3229853 }}</ref> However, this is a fairly basic, global assessment of lung function that does not provide specific information about the lung structure and physiology. For structural information, [[CT scan|X-Ray CT]] is most commonly used, but it exposes the patient to high doses of [[ionizing radiation]] and it provides no functional information<ref>{{cite journal | vauthors = Zhu X, Yu J, Huang Z | title = Low-dose chest CT: optimizing radiation protection for patients | journal = AJR. American Journal of Roentgenology | volume = 183 | issue = 3 | pages = 809–816 | date = September 2004 | pmid = 15333374 | doi = 10.2214/ajr.183.3.1830809 }}</ref> Conventional <sup>1</sup>H MRI is not effective in the lung airspace because of the minimal [[Proton density MRI|proton density]]. <sup>129</sup>Xe gas MRI provides detailed, specific information about lung structure and function that are not safely or efficiently obtainable by existing technologies.<ref name=":0" />
<sup>129</sup>Xe gas MRI is being researched as a diagnostic test for respiratory diseases, such as [[Chronic obstructive pulmonary disease|COPD]], [[asthma]], and [[emphysema]]. [[Spirometry]] pulmonary function tests are used to determine the condition of lung function.<ref>{{cite journal | vauthors = Ranu H, Wilde M, Madden B | title = Pulmonary function tests | journal = The Ulster Medical Journal | volume = 80 | issue = 2 | pages = 84–90 | date = May 2011 | pmid = 22347750 | pmc = 3229853 }}</ref> However, this is a fairly basic, global assessment of lung function that does not provide specific information about the lung structure and physiology. For structural information, [[CT scan|X-Ray CT]] is most commonly used, but it exposes the patient to high doses of [[ionizing radiation]] and it provides no functional information<ref>{{cite journal | vauthors = Zhu X, Yu J, Huang Z | title = Low-dose chest CT: optimizing radiation protection for patients | journal = AJR. American Journal of Roentgenology | volume = 183 | issue = 3 | pages = 809–816 | date = September 2004 | pmid = 15333374 | doi = 10.2214/ajr.183.3.1830809 }}</ref> Conventional <sup>1</sup>H MRI is not effective in the lung airspace because of the minimal [[Proton density MRI|proton density]]. <sup>129</sup>Xe gas MRI provides detailed, specific information about lung structure and function that are not safely or efficiently obtainable by existing technologies.<ref name=":0" />

=== FDA approval ===
<sup>129</sup>Xe Gas MRI has completed Phase I, II, and III clinical trials, led by Polarean, Inc. Xenon has anesthetic properties when delivered in a high dose;<ref>{{cite journal | vauthors = Esencan E, Yuksel S, Tosun YB, Robinot A, Solaroglu I, Zhang JH | title = XENON in medical area: emphasis on neuroprotection in hypoxia and anesthesia | journal = Medical Gas Research | volume = 3 | issue = 1 | pages = 4 | date = February 2013 | pmid = 23369273 | pmc = 3626616 | doi = 10.1186/2045-9912-3-4 | doi-access = free }}</ref> therefore, it is being investigated not as a device, but as a drug. This distinction has greatly slowed the adoption of <sup>129</sup>Xe gas MRI in the clinic, but is important to guaranteeing safety. In October 2020, Polarean submitted for approval, but the FDA rejected their NDA. Polarean has since resubmitted their application, with the next round of feedback slated for early 2021. Ultimately, much of the future utility of <sup>129</sup>Xe Gas MRI will depend on its receiving FDA approval.


=== Visualizing non-lung tissues ===
=== Visualizing non-lung tissues ===
Line 156: Line 149:
{{Diagnostic radiopharmaceuticals}}
{{Diagnostic radiopharmaceuticals}}
{{Portal bar | Medicine}}
{{Portal bar | Medicine}}
{{Authority control}}


[[Category:Magnetic resonance imaging]]
[[Category:Magnetic resonance imaging]]

Revision as of 05:42, 8 January 2024

Hyperpolarized 129Xe gas magnetic resonance imaging (MRI) is a medical imaging technique used to visualize the anatomy and physiology of body regions that are difficult to image with standard proton MRI. In particular, the lung, which lacks substantial density of protons, is particularly useful to be visualized with 129Xe gas MRI. This technique has promise as an early-detection technology for chronic lung diseases and imaging technique for processes and structures reliant on dissolved gases.[1][2] 129Xe is a stable, naturally occurring isotope of xenon with 26.44% isotope abundance. It is one of two Xe isotopes, along with 131Xe, that has non-zero spin, which allows for magnetic resonance. 129Xe is used for MRI because its large electron cloud permits hyperpolarization and a wide range of chemical shifts. The hyperpolarization creates a large signal intensity, and the wide range of chemical shifts allows for identifying when the 129Xe associates with molecules like hemoglobin. 129Xe is preferred over 131Xe for MRI because 129Xe has spin 1/2 (compared to 3/2 for 131Xe), a longer T1, and 3.4 times larger gyromagnetic ratio (11.78 MHz/T).[3]

Uses

Medical uses

Xenon Xe 129 hyperpolarized
Clinical data
Trade namesXenoview
License data
Routes of
administration
Inhalation
ATC code
  • None
Legal status
Legal status
Identifiers
CAS Number
PubChem CID
UNII
KEGG

Xenon Xe 129 hyperpolarized, sold under the brand name Xenoview, is a hyperpolarized contrast agent indicated for use with magnetic resonance imaging (MRI) for evaluation of lung ventilation, and approved for people aged twelve years of age and older.[4][5] It was approved for medical use in the US in December 2022.[6]

The US Food and Drug Administration (FDA) considers it to be a first-in-class medication.[7]

The FDA approved Xenoview based on evidence from two clinical trials in 83 participants with various lung disorders who were being evaluated for possible lung resection or lung transplantation.[5] The trials were conducted at five sites in the United States and assessed both efficacy and safety of Xenoview.[5] Xenoview was evaluated in two clinical trials of 83 adults with pulmonary disorders who each underwent sequential lung ventilation imaging with Xenoview with MRI and an approved comparator, Xe 133 scintigraphy.[5] In study 1, participants were imaged to help plan possible lung resection.[5] To determine the benefit of Xenoview, estimates of the percentage of lung ventilation predicted to remain after surgery made with Xenoview with MRI and comparator imaging were evaluated for equivalence.[5] In study 2, participants were imaged to help plan possible lung transplantation.[5] To determine the benefit of Xenoview, estimates of the percentage of lung ventilation contributed by the right lung made with Xenoview with MRI and comparator imaging were evaluated for equivalence.[5]

History

Hyperpolarized 129Xe is achieved through spin-exchange optical pumping, a technique developed by Grover et al. in 1978[8] and improved by Happer et al. in 1984.[9] Quantification of 129Xe polarization was first described in 1982 by Bhaskar et al.[10] The use of hyperpolarized 129Xe gas in MRI ex-vivo was first described by Albert et al. in 1994 using excised rat lungs.[11] The first in-vivo human studies with 129Xe MRI were published by Mugler et al. in 1997.[12]

129Xe MRI has largely begun to replace 3He gas MRI, a very similar technology that uses hyperpolarized 3He molecules instead of 129Xe. Grossman et al. began human clinical trials for 3He MRI in 1996. 3He was originally touted as the better gas for hyperpolarized gas MRI because it is more polarizable and has no effects on the body.[1] However, 3He is mostly produced by the beta decay of tritium (3H), which is a product of nuclear warhead production. Additionally, 3He is widely used by the U.S. military to detect smuggled plutonium.[13] These combination of increasing scarcity and increasing demand have combined to make 3He highly expensive, up to more than $1000 per liter.[14]

Safety

129Xe is an inert, non-radioactive, non-toxic, and non-teratogenic molecule that has shown no significant adverse health effects when inhaled for MR imaging.[15][16] One potential area of concern is 129Xe's anesthetic properties when a large volume is inhaled. Xenon shows blood and tissue solubility[15] that allows it to diffuse through the lung membrane and affect the nervous system. The minimum alveolar concentration for 50% of motor response to be prevented (MAC) is 0.71, which is not reached during imaging.[15] Further studies have shown that it provides good circulatory stability when dissolved in blood and does not affect body temperature.[17]

Hyperpolarization

When applying an external magnetic field to gas, half of the nuclear spins of the gas atoms point towards the direction of the magnetic field whereas the other half point in the opposite direction. It is slightly more energetically favorable to be aligned with the magnetic field, meaning that one of the spin states is in slight excess of the other. This excess means that the two spin-states do not completely cancel each other out, creating a magnetic signal which can be observed with MRI. However, for traditional 1H MRI, only about 4 ppm of the spin states do not cancel, so the signal is not particularly strong. This means that only regions with high densities of protons, like muscle tissue can be seen.[1] Hyperpolarization is a means of flipping more of the atoms to have the same spin state so that less of the spin states cancel each other. In the case of 129Xe, this leads to a 104-105 improvement in signal strength.[1]

Polarization Transfer

Hyperpolarization of 129Xe is usually performed using spin-exchange optical pumping (SEOP) using circularly polarized light to add angular momentum of the atoms. However, the polarized light cannot directly transfer angular momentum to the gas nuclei, thus, an alkali metal atom is used as an intermediary.[1][15] Rubidium is often used to accomplish this, where the polarized light is tuned to provide exactly the necessary energy to excite rubidium's valence electron. This process is called optical pumping. In the next step, spin exchange, gas nuclei are introduced to the system and collide with the rubidium. They receive angular momentum in the collisions with rubidium valence electrons, which, by conservation of angular momentum, is in the same direction as the rubidium. Therefore, 129Xe becomes hyperpolarized because there is a large excess of one spin state compared to the other. After this, the 129Xe is extracted, the rubidium is polarized again, and the cycle continues.[1][15]

Required modifications to conventional MRI

Traditional MR scanners need to be modified to detect 129Xe, as 129Xe has a lower gyromagnetic ratio of 11.77 MHz/T compared to that of protons, 42.5 MHz/T. Thus, the Larmor frequency of 129Xe is much lower, which is difficult to detect with conventional narrow-band RF amplifiers set to proton's Larmor frequency. Therefore, a broad-band RF amplifier, for both excitation and receiving, is required.[1] Additionally, the pulse sequence must also accommodate the difference in thermally-polarized protons and polarized 129Xe.[1][18] In proton MRI, a typical pulse sequence would involve a 90° flip then a subsequent T1 longitudinal relaxation to the external magnetic field. T1 relaxation in hyperpolarized gas involves the decay of magnetization and not the return to an external magnetic field, as in thermally-polarized protons.[18] Therefore, after a 90° flip, a hyperpolarized gas nuclei's longitudinal relaxation is negligible, making the longitudinal magnetization remain zero after the flip. As a result, traditional 90° and 180° RF pulses are not desirable.[1][18] A low-angle RF pulse is therefore used to only remove a portion of the total available magnetization of the hyperpolarized 129Xe gas. This produces comparable longitudinal magnetization between protons and 129Xe gas.[18] Furthermore, as an image needs to be acquired within a breath-hold, a fast pulse-sequences, or fast-gradient echos, are used to adequately sample the k-space.[1][18]

Applications

Ventilation MRI

After a patient inhales the hyperpolarized gas, the gas passes through the airways within the lungs. In a healthy lung, the gas is able to travel throughout the lungs. However, in a disease that obstructs airways, such as chronic obstructive pulmonary disease (COPD), asthma, and cystic fibrosis, the hyperpolarized gas is unable to reach certain regions within the lung.[1][18][19] Thus, a spin-density weighted image will produce high signals from normal areas and low signals from diseased regions. 3He was originally used for this type of image, but recently there has been a shift towards to 129Xe due to its availability and cheaper price.[19] Hyperpolarized 3He has historically produced superior images because it is easier to hyperpolarize, but current technology has improved gas polarization of 129Xe to the point where the image quality is similar. Furthermore, 129Xe is more sensitive to obstructions as it is a larger atom than 3He. In addition, an increased inhaled volume of 129Xe results in a comparable SNR to that of 3He, up to 1 vs 0.1-0.3 liters.[1]

Diffusion MRI

Diffusion MRI involves calculating the apparent diffusion coefficient (ADC) of the hyperpolarized gas. Diffusion-sensitizing gradients are applied to induce diffusion based attenuation to calculate the ADC.[1][18] These gradients have an associated b-value, which represents the strength and duration of the gradients. At least 2 different b-value gradients are used to calculate the ADC. The ADC provides information regarding how the structure of the lung restricts the hyperpolarized gas diffusion.[18] The value of the ADC increases in regions of increased space. For example, in healthy lungs, the ADC using 129Xe might be around 0.04 cm2/s whereas the ADC for 129Xe in an open space may be around 0.14 cm2/s.[18] In emphysema, where alveolar structures enlarge, the gas is able to diffuse more freely, resulting in a higher ADC compared to normal regions providing information of disease areas.[1][18] Ultimately, this is a novel imaging modality enabled by 129Xe MRI, and its use is being investigated for Chronic Obstructive Pulmonary Disease, Asthma, Cystic Fibrosis, Long-COVID-19, and other diseases.

Partial pressure of oxygen

The longitudinal relaxation (T1) of the hyperpolarized gas is inversely proportional to the concentration of the oxygen in the lung.[18] The interaction between paramagnetic oxygen significantly decreases the relaxation time, which offers insights into the partial pressure of oxygen (pO2) within regions of the lung. Additionally, the ventilation to perfusion ratio can be calculated from these images.[20] Most research has employed 3He, but improved technology has allowed for comparable results when using 129Xe. However, due to the uptake of 129Xe, its relaxation is much quicker than 3He resulting in higher apparent pO2 if left unaccounted.[18]

Research

Xe Gas MRI of Healthy and Diseased Lungs. Colors show different intensities of Xe Gas.

129Xe gas MRI is being researched as a diagnostic test for respiratory diseases, such as COPD, asthma, and emphysema. Spirometry pulmonary function tests are used to determine the condition of lung function.[21] However, this is a fairly basic, global assessment of lung function that does not provide specific information about the lung structure and physiology. For structural information, X-Ray CT is most commonly used, but it exposes the patient to high doses of ionizing radiation and it provides no functional information[22] Conventional 1H MRI is not effective in the lung airspace because of the minimal proton density. 129Xe gas MRI provides detailed, specific information about lung structure and function that are not safely or efficiently obtainable by existing technologies.[1]

Visualizing non-lung tissues

129Xe gas is most commonly used to visualize the lung because it is a gas. However, small bubbles of xenon gas are capable of dissolving into the bloodstream at the alveoli. As these bubbles travel around the body, they can be used to gain insight into other regions of the body. 129Xe gas is capable of crossing the blood brain barrier, allowing novel study of brain perfusion.r[2]

Improving amount of hyperpolarization

Using hyperpolarized gas to image the lungs is not particularly novel, as the use of 3He was established in the early 2000s.[23] 3He was originally chosen because it was easily hyperpolarized to a very large degree, and therefore generated a very strong signal. Recently, improvements in hyperpolarization techniques have been able to generate more hyperpolarized 129Xe, enabling it to generate comparable images to 3He.

References

  1. ^ a b c d e f g h i j k l m n o Roos JE, McAdams HP, Kaushik SS, Driehuys B (May 2015). "Hyperpolarized Gas MR Imaging: Technique and Applications". Magnetic Resonance Imaging Clinics of North America. 23 (2): 217–229. doi:10.1016/j.mric.2015.01.003. PMC 4428591. PMID 25952516.
  2. ^ a b Rao MR, Stewart NJ, Griffiths PD, Norquay G, Wild JM (February 2018). "Imaging Human Brain Perfusion with Inhaled Hyperpolarized 129Xe MR Imaging". Radiology. 286 (2): 659–665. doi:10.1148/radiol.2017162881. PMID 28858563.
  3. ^ Oros AM, Shah NJ (October 2004). "Hyperpolarized xenon in NMR and MRI" (PDF). Physics in Medicine and Biology. 49 (20): R105–R153. doi:10.1088/0031-9155/49/20/r01. PMID 15566166. S2CID 250857751.
  4. ^ a b "Xenoview- xenon xe 129 hyperpolarized gas". DailyMed. 30 December 2022. Retrieved 21 January 2023.
  5. ^ a b c d e f g h "Drug Trials Snapshots: Xenoview". U.S. Food and Drug Administration. 23 December 2022. Retrieved 8 January 2024. Public Domain This article incorporates text from this source, which is in the public domain.
  6. ^ "FDA Approves Polarean's Xenoview (xenon Xe 129 hyperpolarized) for use with MRI for the Evaluation of Lung Ventilation" (Press release). Polarean Imaging. 28 December 2022. Retrieved 31 August 2023 – via GlobeNewswire.
  7. ^ "Advancing Health Through Innovation: New Drug Therapy Approvals 2022". U.S. Food and Drug Administration (FDA). 10 January 2023. Retrieved 22 January 2023. Public Domain This article incorporates text from this source, which is in the public domain.
  8. ^ Grover BC (6 February 1978). "Noble-Gas NMR Detection through Noble-Gas-Rubidium Hyperfine Contact Interaction". Physical Review Letters. 40 (6): 391–392. Bibcode:1978PhRvL..40..391G. doi:10.1103/PhysRevLett.40.391. ISSN 0031-9007.
  9. ^ Happer W, Miron E, Schaefer S, Schreiber D, Van Wijngaarden WA, Zeng X (1 June 1984). "Polarization of the nuclear spins of noble-gas atoms by spin exchange with optically pumped alkali-metal atoms". Physical Review A. 29 (6): 3092–3110. Bibcode:1984PhRvA..29.3092H. doi:10.1103/PhysRevA.29.3092. ISSN 0556-2791.
  10. ^ Bhaskar ND, Happer W, McClelland T (5 July 1982). "Efficiency of Spin Exchange between Rubidium Spins and Xe 129 Nuclei in a Gas". Physical Review Letters. 49 (1): 25–28. doi:10.1103/PhysRevLett.49.25. ISSN 0031-9007.
  11. ^ Marshall H, Stewart NJ, Chan HF, Rao M, Norquay G, Wild JM (February 2021). "In vivo methods and applications of xenon-129 magnetic resonance". Progress in Nuclear Magnetic Resonance Spectroscopy. 122: 42–62. doi:10.1016/j.pnmrs.2020.11.002. PMC 7933823. PMID 33632417.
  12. ^ Mugler JP, Driehuys B, Brookeman JR, Cates GD, Berr SS, Bryant RG, et al. (June 1997). "MR imaging and spectroscopy using hyperpolarized 129Xe gas: preliminary human results". Magnetic Resonance in Medicine. 37 (6): 809–815. doi:10.1002/mrm.1910370602. PMID 9178229. S2CID 27232819.{{cite journal}}: CS1 maint: overridden setting (link)
  13. ^ Albert MS, Balamore D (1998). "Development of hyperpolarized noble gas MRI". Nuclear Instruments and Methods in Physics Research Section A. 402 (2–3): 441–453. Bibcode:1998NIMPA.402..441A. doi:10.1016/s0168-9002(97)00888-7. PMID 11543065.
  14. ^ Adee S (31 August 2010). "Physics Projects Deflate for Lack of Helium-3". IEEE Spectrum. Retrieved 5 December 2021.
  15. ^ a b c d e Kennedy RR, Stokes JW, Downing P (February 1992). "Anaesthesia and the 'inert' gases with special reference to xenon". Anaesthesia and Intensive Care. 20 (1): 66–70. doi:10.1177/0310057X9202000113. PMID 1319119. S2CID 29886337.
  16. ^ Driehuys B, Martinez-Jimenez S, Cleveland ZI, Metz GM, Beaver DM, Nouls JC, et al. (January 2012). "Chronic obstructive pulmonary disease: safety and tolerability of hyperpolarized 129Xe MR imaging in healthy volunteers and patients". Radiology. 262 (1): 279–289. doi:10.1148/radiol.11102172. PMC 3244666. PMID 22056683.{{cite journal}}: CS1 maint: overridden setting (link)
  17. ^ Marx T, Schmidt M, Schirmer U, Reinelt H (October 2000). "Xenon anaesthesia". Journal of the Royal Society of Medicine. 93 (10): 513–517. doi:10.1177/014107680009301005. PMC 1298124. PMID 11064688.
  18. ^ a b c d e f g h i j k l Mugler JP, Altes TA (February 2013). "Hyperpolarized 129Xe MRI of the human lung". Journal of Magnetic Resonance Imaging. 37 (2): 313–331. doi:10.1002/jmri.23844. PMC 3558952. PMID 23355432.
  19. ^ a b Ebner L, Kammerman J, Driehuys B, Schiebler ML, Cadman RV, Fain SB (January 2017). "The role of hyperpolarized 129xenon in MR imaging of pulmonary function". European Journal of Radiology. 86: 343–352. doi:10.1016/j.ejrad.2016.09.015. PMC 5195899. PMID 27707585.
  20. ^ Rizi RR, Baumgardner JE, Ishii M, Spector ZZ, Edvinsson JM, Jalali A, et al. (July 2004). "Determination of regional VA/Q by hyperpolarized 3He MRI". Magnetic Resonance in Medicine. 52 (1): 65–72. doi:10.1002/mrm.20136. PMID 15236368. S2CID 25053184.{{cite journal}}: CS1 maint: overridden setting (link)
  21. ^ Ranu H, Wilde M, Madden B (May 2011). "Pulmonary function tests". The Ulster Medical Journal. 80 (2): 84–90. PMC 3229853. PMID 22347750.
  22. ^ Zhu X, Yu J, Huang Z (September 2004). "Low-dose chest CT: optimizing radiation protection for patients". AJR. American Journal of Roentgenology. 183 (3): 809–816. doi:10.2214/ajr.183.3.1830809. PMID 15333374.
  23. ^ van Beek EJ, Wild JM (1 December 2005). "Hyperpolarized 3-helium magnetic resonance imaging to probe lung function". Proceedings of the American Thoracic Society. 2 (6): 528–32, 510. doi:10.1513/pats.200507-071DS. PMID 16352759.